Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Popat

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2020
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trialS Popat, A Curioni-Fontecedro, U Dafni, et al.
The British Journal of Radiology|June 3, 2026
Stereotactic Radiosurgery (SRS) for Small Cell Lung Cancer (SCLC) brain metastases: a real-world UK tertiary centre experienceD J McMahon, A John, T Ketpueak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 15, 2025
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trialE Felip, S Popat, U Dafni, et al.
Annals of Human Genetics|August 14, 2002
Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac diseaseS Popat, N Hearle, L Hogberg, et al.
Journal of Medical Genetics|May 16, 2002
Genome screening of coeliac diseaseS Popat, S Bevan, C P Braegger, et al.
Journal of Medical Genetics|October 3, 1999
Contribution of the MHC region to the familial risk of coeliac diseaseS Bevan, S Popat, C P Braegger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialS Peters, J-L Pujol, U Dafni, et al.
ESMO Open|November 30, 2024
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancerS-H Lee, J Menis, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2022
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerA Passaro, N Leighl, F Blackhall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2019
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryJ Mazieres, A Drilon, A Lusque, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2020
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trialS Popat, A Curioni-Fontecedro, U Dafni, et al.
The British Journal of Radiology|June 3, 2026
Stereotactic Radiosurgery (SRS) for Small Cell Lung Cancer (SCLC) brain metastases: a real-world UK tertiary centre experienceD J McMahon, A John, T Ketpueak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 15, 2025
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trialE Felip, S Popat, U Dafni, et al.
Annals of Human Genetics|August 14, 2002
Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac diseaseS Popat, N Hearle, L Hogberg, et al.
Journal of Medical Genetics|May 16, 2002
Genome screening of coeliac diseaseS Popat, S Bevan, C P Braegger, et al.
Journal of Medical Genetics|October 3, 1999
Contribution of the MHC region to the familial risk of coeliac diseaseS Bevan, S Popat, C P Braegger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialS Peters, J-L Pujol, U Dafni, et al.
ESMO Open|November 30, 2024
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancerS-H Lee, J Menis, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2022
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerA Passaro, N Leighl, F Blackhall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2019
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryJ Mazieres, A Drilon, A Lusque, et al.
Pageof 9